Insights

  • Date

  • Content Type

  • Reset

Blog

Recombinant viruses driving game-changing therapies

18.02.20

By Jörg Schneider

Recent years saw the approval of several Advanced Therapy Medicinal Products (ATMPs) using recombinant viruses and the pipeline...

Read More

Blog

How iPS cells are changing drug development and disease modelling

5.02.20

By Masin Abo-Rady

The development of drugs is time and money-expensive. Lack of efficacy and drug toxicity cause failure of late-stage...

Read More

Blog

Are biomarkers ushering a new era in vaccine discovery?

2.12.19

By Ilona Baraniak

Through many decades vaccines have helped us to control a wide range of pathogens. However, vaccine development...

Read More

Blog

Best Practices in Dealing with Novel Excipients

26.11.19

By Mariya Gromova and Noemi Lupo

Novel excipients play a crucial role in bringing new, improved and safer drugs to the pharmaceutical market....

Read More

Blog

Do We Need an EU Vaccine Regulation?

8.11.19

By Michael Pfleiderer

Neglected diseases, neglected vaccines. Unprecedented challenges, like the recurrence of known and new infectious diseases pose one...

Read More

Blog

Opportunities to improve the PIP outcome during the PIP submission process

31.10.19

By Linsey Reavie

The process of preparing a PIP can be lengthy and challenging, with numerous potential pitfalls along the...

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more